Skip to main content

Nebulizer Market Size to Surpass USD 1,202.5 Million by 2029, exhibiting a CAGR of 4.8%

As per the report by Fortune Business Insights, the global Nebulizer Market size is projected to reach USD 1,202.5 Million in 2029, at a CAGR of 4.8% during the forecast period, 2022-2029

Pune, India, May 24, 2023 (GLOBE NEWSWIRE) — According to Fortune Business Insights, global Nebulizer Market size was valued at USD 833.6 million in 2021 and is projected to grow from USD 863.4 million in 2022 to USD 1,202.5 million by 2029, exhibiting a CAGR of 4.8% during the forecast period. Increasing respiratory disorders and robust demand for innovative respiratory drug delivery services are expected to elevate the market’s progress. Fortune Business Insights presents this information in its report titled “Nebulizer Market Forecast, 2022-2029”.


Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nebulizers-market-100707


Key Industry Development

PARI Pharma GmbH declared the authorization of its LAMIRA Nebulizer System to deliver Insmed’s ARIKAYCE in Japan.

Key Takeaways:

  • The increasing incidence of respiratory disorders globally and the rising geriatric population are likely to fuel the market growth during the forecast period.
  • Rapid adoption of nebulizer among the patient population is likely to drive their usage during the forecast period.
  • The market size in North America stood at USD 382.7 million in 2021.

Discover the Leading Players Featured in the Report:

“Companies leading the Nebulizer market are OMRON Healthcare, Inc. (Japan), Koninklijke Philips N.V. (Netherlands), PARI Respiratory Equipment, Inc. (U.S.), DeVilbiss Healthcare LLC (U.S.), Briggs Healthcare (U.S.), GF HEALTH PRODUCTS, INC. (U.S.), Trudell Medical International (Canada), Allied Healthcare Products, Inc. (U.S.), Teleflex Medical, Inc. (U.S.)

Report Scope & Segmentation:

Report CoverageDetails
Forecast Period2022 to 2029
Forecast Period 2022 to 2029 CAGR4.8%
2029 Value ProjectionUSD 1,202.5 Million
Base Year2021
Market Size in 2022USD 863.4 Million
Historical Data2018 to 2020
No. of Pages128
Segments coveredBy Type, Modality, End-user, and Region


Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/nebulizers-market-100707


Drivers and Restraints

Rising Respiratory Disorders to Propel Market Progress

Nebulizers are drug delivery devices that deliver medicines in the form of a mist in the lungs. Rising respiratory disorders are likely to foster the product adoption. For example, as per the Asthma and Allergy Foundation of America’s strategy, in April 2022, nearly 25.0 million people in the U.S. suffered from asthma. Poor air quality, rising pollution, and the presence of several factories are expected to foster the demand for the device. Furthermore, rising healthcare costs enhanced the adoption of home healthcare services, thereby elevating the demand for effective medical procedures and equipment. In addition, the robust demand for inhaled drug delivery devices is expected to drive the nebulizer market growth.

However, disease transmission risks and the availability of alternative treatment methods may hamper the market growth.

Segments

Jet Segment to Dominate Attributable to its Clinically Proven Advantages

By type, the market is segmented into jet, mesh, and ultrasonic. The jet segment is expected to lead due to its clinically proven benefits.

Table-top Segment to Lead Owing to its Unique Characteristics

As per modality, the market is bifurcated into portable and table-top. The table-top segment is expected to lead due to the availability of reimbursement policies in developed markets, with operational benefits offered by these devices.

Homecare Segment to Dominate Attributable to Rising Shift to Medical Devices

Based on end-user, the market is categorized into hospitals, clinics, and homecare settings. The homecare segment is expected to lead due to the rising shift toward medical devices.

Regionally, the market is clubbed into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.


Quick Buy – Nebulizer Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100707

 

Segmentation:

By Type

  • Jet Nebulizer
  • Ultrasonic Nebulizer
  • Mesh Nebulizer

By Modality

  • Portable
  • Table-top

By End-user

  • Hospitals
  • Clinics
  • Homecare Settings

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • Middle East & Africa (South Africa, GCC Countries, Rest of the Middle East & Africa)

Regional Insights

Higher Prevalence of Asthma to Propel Market Progress in North America

North America is projected to dominate the nebulizer market share due to the higher prevalence of asthma. The market in North America stood at USD 382.7 million in 2021 and is expected to gain a huge portion of the global market share in the coming years. Furthermore, the higher prevalence of asthma is expected to enhance the demand for medical devices.

In Europe, the increasing prevalence of respiratory diseases and robust adoption of the device is expected to boost industry growth. Further, the rising prevalence of respiratory diseases is expected to enhance market progress.

In Asia Pacific, the increasing prevalence of chronic respiratory disorders is likely to elevate the demand for nebulizers. This factor may propel market progress in the region.

Competitive Landscape

Crucial Players Deploy Collaborations to Enhance their Brand Image

The prominent companies operating in the market deploy acquisition strategies to enhance their brand image. For example, PARI GmbH partnered with TWT Digital Health (TWT) in July 2021 to develop the PARI connect application. This application also offers Bluetooth communication with the eTrack controller, a controller unit for PARI’s eFlow Technology nebulizer. Further, several players deploy research and development, mergers, acquisitions, partnerships, novel product launches, innovations, and industrial automation to enhance their market position.


Speak to Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/nebulizers-market-100707


FAQs

How big is the nebulizer market?

Nebulizer Market size was USD 863.4 million in 2022. It is expected to reach USD 1,202.5 million by 2029.

How fast is the nebulizer market growing?

The Nebulizer Market will exhibit a CAGR of 4.8% during the forecast period, 2022-2029.

Related Reports:

Smart Inhalers Market Size, Share, Revenue Forecast and Opportunities

Nasal Drug Delivery Market Overview, Industry Share and Forecast

Respiratory Devices Market Size, Share, Opportunities & Analysis

Wound Care Devices Market Share, Size, Analysis Forecast and Opportunities

Mobility Devices Market Share, Industry Growth, Forecast and Opportunities

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

9th Floor, Icon Tower,

Baner – Mahalunge Road,

Baner, Pune-411045,

Maharashtra, India.

Phone:

U.S. :+1 424 253 0390

U.K. : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.